More and more, pharma companies are making real bets in digital health, and reorganizing their businesses to put some power behind those efforts. The space is, in some ways, quieter than it was this time last year, but there’s reason to believe that quiet is a calm before a storm of activity, driven more by pharma’s tendency to keep early-stage projects close to the chest than by a lack of...
Propeller Health and Boehringer Ingelheim announced a new commercial partnership. Under the partnership, COPD and asthma patients using Boehringer's Respimat inhaler will have the opportunity to enroll in a program at select health systems that will monitor their adherence via a Propeller sensor and improve their engagement in their health.
"So far we have developed a popular Bluetooth-enabled...
GSK's Ellipta inhaler
GlaxoSmithKline and Madison, Wisconsin-based Propeller Health announced a partnership today in which Propeller will develop and manufacture a custom sensor for GSK's Ellipta inhaler for COPD patients.
Like the other inhaler sensors Propeller has developed, the device will record when and where the patient uses the inhaler and wirelessly transmit that information to GSK ...
Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and partnership deals have shown clearly that the space is of interest. (MobiHealthNews is helping to put on two pharma-related events at the mHealth Summit next week -- be sure to join us if you'll be in...
Propeller Health is working with Boehringer Ingelheim.
Pharma's investment in the digital health space is getting more and more real and substantive as companies move beyond the pilot stage and start to launch real digital health interventions, from Teva buying up smart inhaler company Gecko to Otsuka gearing up to launch a commercial drug integrated with a Proteus sensor.
But digital...
Madison, Wisconsin-based Propeller Health has secured two new FDA clearances for new sensors that are designed to work with two particular inhalers on the market: the Diskus inhaler from GlaxoSmithKline and the Respimat inhaler from Boehringer Ingelheim. Unlike previous FDA clearances for Propeller, the new clearances actually allow Propeller to market its new devices as improving — not just...
Pharma-related digital health news picked up this week. Boehringer Ingelheim has teamed up with Sutter Health to research COPD interventions; BioDelivery Science created an app to help users deal with prediction opioid addictions; and Canaan Partners' Julie Papanek talked to the Wall Street Journal about pharma's emerging role in digital health.
Boehringer Ingelheim Pharmaceuticals, the...
Vancouver-based Ayogo has raised $2.5 million from Merck Global Health Innovation Fund (GHI), Excel Venture Management, and 7Wire Ventures for it's patient engagement offering, an app called Empower.
The app, designed for providers and pharma companies, helps patients with chronic conditions stick to their care plans. Patients can use the app to set their own goals, track their health and...
Boehringer Ingelheim is a pretty familiar name to people who follow mobile health moves from pharma companies. The large, privately-owned German firm has been involved in pilots with game developer Ayogo, smart pill bottle maker AdhereTech, and now-defunct behavior change platform Healthrageous.
While its partners have talked up these pilots, up until now the company itself has been pretty quiet...
AdhereTech's first generation smart pill bottle.
Smart pill bottle maker AdhereTech has raised $1.75 million from undisclosed investors, the company's first non-seed round. CEO Josh Stein told MobiHealthNews the funding is for a very specific need -- redesigning the prototype bottle that AdhereTech has been using in its pilots.
"Basically we’re raising a series A because we want to redesign...
